Trilogy Capital
DXCM icon

Trilogy Capital’s DexCom DXCM Stock Holding History

Trilogy Capital’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$521K Buy
6,035
+90
+2% +$7.49K 0.02% 273
2026
Q2 		$400K Hold
5,945
– – 0.02% 296
2026
Q1 		$373K Sell
5,945
-803
-12% -$55.9K 0.02% 294
2025
Q4 		$448K Hold
6,748
– – 0.02% 257
2025
Q3 		$454K Buy
6,748
+3
+0% +$237 0.02% 259
2025
Q2 		$589K Buy
6,745
+35
+0.5% +$2.74K 0.03% 217
2025
Q1 		$458K Hold
6,710
– – 0.02% 228
2024
Q4 		$522K Sell
6,710
-157
-2% -$11.6K 0.03% 223
2024
Q3 		$460K Sell
6,867
-9,420
-58% -$774K 0.02% 230
2024
Q2 		$1.85M Buy
16,287
+12,895
+380% +$1.63M 0.1% 134
2024
Q1 		$470K Buy
+3,392
New +$426K 0.03% 204
2018
Q4 		– Sell
-160
Closed -$6K – 251
2018
Q3 		$6K Buy
+160
New +$4.96K ﹤0.01% 372
2018
Q2 		– Sell
-140
Closed -$3K – 586
2018
Q1 		$3K Buy
+140
New +$2.07K ﹤0.01% 346

Other funds holding DXCM

Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
Fisher Funds Management
Fisher Funds Management Auckland, New Zealand $3.44B AUM 17.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Beacon Investment Advisory Services
Beacon Investment Advisory Services Morristown, New Jersey $2.66B AUM 29.77% 1-Year Est. Return
Gradient Investments
Gradient Investments Arden Hills, Minnesota $7B AUM 14.85% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
Bank Pictet & Cie (Europe)
Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.31B AUM 25.55% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
Czech National Bank
Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return
HH
HWG Holdings Houston, Texas $434M AUM 42.17% 1-Year Est. Return

Trilogy Capital's DXCM Position: Q3 2026 in Review

Trilogy Capital increased its DexCom (DXCM) stake by 1.5% in Q3 2026, buying an estimated $7.49K and bringing the position to 6,035 shares worth $521K. The position accounts for 0.02% of the portfolio, ranked #273.

Trilogy Capital first reported a position in DXCM in Q1 2018 and has held it in 13 quarters since. The position peaked at $1.85M in Q2 2024. 150 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • Trilogy Capital held 6,035 shares of DexCom worth $521K as of Q3 2026.
  • Trilogy Capital bought 90 DexCom shares in Q3 2026, an estimated $7.49K.
  • DexCom made up 0.02% of Trilogy Capital's portfolio in Q3 2026, its #273 holding.
  • Trilogy Capital first reported a position in DexCom in Q1 2018 and has held it in 13 quarters since.
  • Trilogy Capital's DexCom position peaked at $1.85M in Q2 2024.
  • 150 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on Trilogy Capital's 13F filing for Q3 2026, filed 20 Oct 2026.